Gyre Therapeutics (GYRE) Stock: Buy, Sell, or Hold?
GYRE - Gyre Therapeutics, Inc. Common Stock
$6.73
-0.01 (-0.15%)
âŧ
5d:
+4.5%
30d:
+1.05%
90d:
+11.06%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When GYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GYRE is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GYRE is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: GYRE is currently trading at $6.73, which is considered fair relative to its 30-day fair value range of $6.43 to $6.92. From a valuation perspective, the stock is trading at a discount (Forward PE: -28.6) compared to its historical average (45.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GYRE is in a downtrend. Immediate support is located at $6.32, while resistance sits at $7.26.
Market Sentiment: GYRE scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.67 (+177.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GYRE is in a downtrend. Immediate support is located at $6.32, while resistance sits at $7.26.
Market Sentiment: GYRE scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.67 (+177.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$6.43 -
$6.92
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 177.4% below Wall St target ($18.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.43 -
$6.92
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$6.32
Resistance Level
$7.27
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-28.64
Wall Street Target
$18.67
(+177.4%)
Revenue Growth (YoY)
-2.1%
Earnings Growth (YoY)
166.2%
Profit Margin
-19.3%
PE vs Historical
-28.6 vs 45.4
CHEAP
Share & Embed Analysis
Last updated: September 12, 2026 10:15 AM ET
Data refreshes hourly during market hours. Next update: 11:15 AM
Data refreshes hourly during market hours. Next update: 11:15 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 48 HOLD |
